Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy

Table 1 Characteristics of solid tumor patients receiving coronavirus disease 2019 vaccination

Patient characteristics	n = 210, %
Age at vaccination, median (range), yr	70 (23-91)
Sex
Male	102 (49)
Female	108 (51)
Race
Caucasian	183 (87)
African American	19 (9)
Other	8 (4)
Site of primary tumor
Gastrointestinal	92 (44)
Thoracic	64 (30)
Genitourinary	37 (18)
Other	17 (8)
Type of systemic therapy
Chemotherapy	117 (56)
Immunotherapy	51 (24)
Targeted therapy	42 (20)

Table 2 Adverse events (AEs) observed with coronavirus disease 2019 vaccination in patients with solid tumors receiving systemic therapies

	Chemotherapy	Immunotherapy	Targeted therapy
Patient number	117	51	42
Median age (yr)	69	72	68
Gender (Male/Female)	55/62	29/22	18/24
Type of vaccine administered(Moderna/Pfizer/J&J)	47/65/5	23/24/4	19/21/2
AEs (Grade 1 + 2), number (%)	37 (60)	18 (29)	7 (11)
Therapy delayed because of AEs, #	1	2	0

AEs: Adverse events.

Table 3 Adverse events associated with coronavirus disease 2019 vaccination in published studies

Ref.	Sample size (n)	Cancer type	Systemic therapy	Vaccines administered	Patients with Grade 3 or worse AE, %	Immune-related AEs	Comment
Oosting et al[23]	544	Solid Tumors	Chemotherapy; Immunotherapy; Chemoimmunotherapy	mRNA-1273 (Moderna)	10/544 (1.8%)	4% in both immunotherapy and chemoimmunotherapy group	Total 4 serious AEs were potentially related to the vaccination
Cavann et al[24]	257	Solid Tumors	Chemotherapy; Immunotherapy; Chemoimmunotherapy; Chemotherapy plus biological therapy; Biologic therapy	PfizerModerna	0/257 (0%)	NA	Approximately 1/3rd of patients reported mild local reactions (pain, erythema) at the injection site
Waissengrin et al[25]	134	Solid Tumors	Immune checkpoint inhibitor; Chemoimmunotherapy	BNT162b2 mRNA vaccine (Pfizer)	0/134 (0%)	Nonattributable to the vaccination	Fatigue (34%), headache (16%), muscle pain (34%)
Di Noia et al[26]	816	Solid Tumors	Chemotherapy; Immunotherapy; Chemoimmunotherapy; Targeted therapy	Pfizer	3.3% after the 1st dose, 1.4% after the second dose	NA	AE occurred in 359 (44%) and 301 (38.3%) patients after the first and second dose, respectively
Shmueli et al[27]	129	Solid Tumors	Chemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; Radiotherapy	Pfizer	0/129 (0%)	NA	AE was reported by 39% of patients after the first dose and 58% of patients after the second dose- all mild to moderate in severity
Tamura et al[29]	120	Solid Tumor	Chemotherapy; Immunotherapy; Targeted Therapy; Chemoimmunotherapy	Pfizer Moderna	0/120 (0%); CTCAE was not used	NA	Study limited to patients receiving treatment for lung cancer only. No serious AEs or treatment delay was observed
Kian et al[28]	210	Solid & Non-Solid Tumors	Chemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; Radiotherapy; Radio-hormonal; Chemo-biological	Pfizer	0.004% after 1st dose, 1.9% after the second dose	NA	AE occurred in 65 (31%) and 65 (31%) patients after the first and second dose, respectively. Injection site pain was the most common AE after both doses

AEs: Adverse events; NA: Not available.